A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis

Farnesoid X receptor (FXR) agonists have been validated to benefit patients with nonalcoholic steatohepatitis (NASH), although improvements in efficacy and/or tolerability remain elusive.

Source: Journal of Hepatology - February 10, 2021 Category: Gastroenterology Authors: Stephen A. Harrison, Mustafa R. Bashir, Kyoung-Jin Lee, Jennifer Shim-Lopez, Jonathan Lee, Brandee Wagner, Nicholas D. Smith, Hubert C. Chen, Eric J. Lawitz Source Type: research